TUSTIN, CA--(Marketwire - Feb 27, 2012) - Peregrine Pharmaceuticals, Inc. (NASDAQ: [ PPHM ]), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and infectious diseases, today announced that Steven King, president and CEO, will present at the following two investor conferences in March:

• 32^nd Cowen Health Care Conference on Monday, March 5, 2012, at 4:10pm Eastern Time at the Marriott Copley Hotel in Boston
• 24^th Annual ROTH Conference on Monday, March 12, 2012, at 11:00am Pacific Time at the Ritz Carlton Hotel in Laguna Nigel

Peregrine's presentation at the 24^th Annual Roth Conference will be webcast live and available for replay until April 2, 2012 at: [ http://ir.peregrineinc.com/events.cfm ]

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and infectious disease with its lead product candidate bavituximab and novel brain cancer agent Cotara^®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. ([ www.avidbio.com ]), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at [ www.peregrineinc.com ].